Skip to main content

Advertisement

ADVERTISEMENT

News

Non-Cardiac Surgery
09/09/2024
The ASSURE DES trial showed no difference in ischemic events or major bleeding between aspirin monotherapy and no antiplatelet therapy in patients with drug-eluting stent(s) undergoing non-cardiac surgery, with a modest increase in minor...
The ASSURE DES trial showed no difference in ischemic events or major bleeding between aspirin monotherapy and no antiplatelet therapy in patients with drug-eluting stent(s) undergoing non-cardiac surgery, with a modest increase in minor...
The ASSURE DES trial showed no...
09/09/2024
Cath Lab Digest
TAVI
09/09/2024
In the NOTION-3 trial, performing percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve implantation (TAVI) significantly reduced death, myocardial infarction or urgent revascularisation compared with TAVI...
In the NOTION-3 trial, performing percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve implantation (TAVI) significantly reduced death, myocardial infarction or urgent revascularisation compared with TAVI...
In the NOTION-3 trial,...
09/09/2024
Cath Lab Digest

Advertisement

T-TEER
09/09/2024
In the Tri.fr trial, tricuspid transcatheter edge-to-edge repair (T-TEER) plus optimal medical therapy resulted in a significant improvement of the primary endpoint including death, cardiovascular hospitalisation, functional class and...
In the Tri.fr trial, tricuspid transcatheter edge-to-edge repair (T-TEER) plus optimal medical therapy resulted in a significant improvement of the primary endpoint including death, cardiovascular hospitalisation, functional class and...
In the Tri.fr trial, tricuspid...
09/09/2024
Cath Lab Digest
MEETINGS
09/06/2024
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of...
09/06/2024
Cath Lab Digest
TAVR
09/06/2024
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the...
09/06/2024
Cath Lab Digest

Advertisement

Risk Factors
09/05/2024
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart...
09/05/2024
Cath Lab Digest
Pharmaceutical Therapy
09/04/2024
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC...
09/04/2024
Cath Lab Digest
Pharmaceutical Therapy
09/04/2024
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only...
09/04/2024
Cath Lab Digest

Advertisement

AI
09/04/2024
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the...
09/04/2024
Cath Lab Digest
Radiation Protection
09/04/2024
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an...
09/04/2024
Cath Lab Digest

Advertisement